Table 5 Association between immunostaining for myosin VI, E-cadherin and beta-catenin.
From: Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma
| Â | Â | Nuclear myosin VI | p-value | |
|---|---|---|---|---|
| Â | Â | negative | positive | Â |
Nuclear beta-catenin | negative | 59 (74%) | 21 (26%) | Â |
| Â | positive | 33 (52%) | 30 (48%) | 0.008 |
| Â | Â | Cytoplasmic myosin VI | Â | |
| Â | Â | Negative | positive | Â |
Cytoplasmic beta-catenin | negative | 38 (29%) | 92 (71%) | Â |
| Â | positive | 3 (23%) | 10 (77%) | 0.8* |
| Â | Â | Nuclear myosin VI | Â | |
| Â | Â | negative | positive | Â |
Nuclear E-cadherin | negative | 61 (70%) | 26 (30%) | Â |
| Â | positive | 32 (56%) | 25 (44%) | 0.09 |
| Â | Â | Cytoplasmic myosin VI | Â | |
| Â | Â | negative | positive | Â |
Membranous E-cadherin | negative | 40 (31%) | 90 (69%) | Â |
| Â | positive | 1 (7%) | 13 (93%) | 0.07* |
| Â | Â | Nuclear beta-catenin | Â | |
| Â | Â | negative | positive | Â |
Nuclear E-cadherin | negative | 66 (75%) | 22 (25%) | Â |
| Â | positive | 16 (27%) | 43 (73%) | <0.001 |
| Â | Â | Cytoplasmic beta-catenin | Â | |
| Â | Â | negative | positive | Â |
Membranous E-cadherin | negative | 124 (93%) | 9 (7%) | Â |
| Â | positive | 10 (71%) | 4 (29%) | 0.02* |